PDI to Sell Commercial Services Business, Focus on Molecular Diagnostics | GenomeWeb

NEW YORK (GenomeWeb) – As part of its effort to focus on its molecular diagnostics business, PDI announced today that it has agreed to sell off its biomedical commercialization and marketing services business to Publicis Group for up to roughly $48 million.

PDI also said it will assume the name of its molecular diagnostics subsidiary, Interpace Diagnostics, and chance its Nasdaq trading symbol to IDXG. The sale is expected to close in the fourth quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.